Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.

ABSTRACT:

Background

Medulloblastoma (MB) is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the children undergoing treatment. Thus, there is an urgent need for improved, targeted therapies that minimize these harmful side effects.

Methods

We identified candidate drugs for MB using a network-based systems-pharmacogenomics approach: based on results from a functional genomics screen, we identified a network of interactions implicated in human MB growth regulation. We then integrated drugs and their known mechanisms of action, along with gene expression data from a large collection of med

SUBMITTER: Genovesi LA 

PROVIDER: S-EPMC8215804 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature